JNJ Johnson and Johnson

By Colin Kellaher

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit Thursday said the European Commission approved its Spravato nasal spray for adults with treatment-resistant major depressive disorder.

The drug maker said the approval covers Spravato in combination with a selective serotonin reuptake inhibitor or serotonin and norepinephrine reuptake inhibitor for adults with treatment-resistant depression, meaning they haven't responded to at least two different treatments.

Janssen said major depressive disorder affects about 40 million people across Europe and is the leading cause of disability worldwide.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 19, 2019 06:17 ET (11:17 GMT)

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024